However, how Trp53R172H, which reportedly elevates H-RAS activity in head and neck squamous cell carcinomas [16] and is a gain-of-function mutation [17], affects the trajectory of KRAS and CDKN2A mutations in PC has not yet been reported. This evidence concerns the gene CDKN2A and pachyonychia congenita.